Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- The level of fasting and post prandial BG level
研究概览
简要总结
Evaluation of the glycemic efficacy of cabergoline on diabetic patients
详细描述
Type 2 diabetes mellitus (DM) is a progressive metabolic disorder that is associated with basal hyperinsulinemia, insulin resistance and impaired insulin release. Glycemic control is a fundamental part of the management of type 2 DM and difficult to achieve. Different antidiabetic agents can handle diabetic metabolic abnormalities. The development of antidiabetic agentswith novel mechanisms of action is highly desirable. Cabergoline, a long acting D2 agonist, is expected to play a role in the glycemic control.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Diabetic patients.
排除标准
- •Other drugs administration
研究组 & 干预措施
Cabergoline
cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
干预措施: Cabergoline (Drug)
Gliclazide
gliclazide (60-120 mg) once daily
干预措施: Gliclazide (Drug)
结局指标
主要结局
The level of fasting and post prandial BG level
时间窗: 4 months
Fasting and post prandial BG level will be measured after 4 months
次要结局
未报告次要终点
研究者
Sherief Abd-Elsalam
PhDTropical Medicine
Tanta University